- Home
- NBBK vs PHAR Comparison
NBBK vs PHAR Comparison
Compare NBBK & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- PHAR
- Stock Information
- Founded
- NBBK 1892
- PHAR 1988
- Country
- NBBK United States
- PHAR Netherlands
- Employees
- NBBK N/A
- PHAR N/A
- Industry
- NBBK
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NBBK
- PHAR Health Care
- Exchange
- NBBK Nasdaq
- PHAR Nasdaq
- Market Cap
- NBBK 661.3M
- PHAR 718.1M
- IPO Year
- NBBK N/A
- PHAR N/A
- Fundamental
- Price
- NBBK $16.22
- PHAR $10.41
- Analyst Decision
- NBBK Buy
- PHAR Strong Buy
- Analyst Count
- NBBK 1
- PHAR 3
- Target Price
- NBBK $22.00
- PHAR $30.00
- AVG Volume (30 Days)
- NBBK 295.7K
- PHAR 2.5K
- Earning Date
- NBBK 07-23-2025
- PHAR 07-31-2025
- Dividend Yield
- NBBK N/A
- PHAR N/A
- EPS Growth
- NBBK 421.39
- PHAR N/A
- EPS
- NBBK 1.18
- PHAR N/A
- Revenue
- NBBK $169,131,000.00
- PHAR $320,708,000.00
- Revenue This Year
- NBBK N/A
- PHAR $13.31
- Revenue Next Year
- NBBK N/A
- PHAR $7.68
- P/E Ratio
- NBBK $13.79
- PHAR N/A
- Revenue Growth
- NBBK 27.71
- PHAR 24.13
- 52 Week Low
- NBBK $14.20
- PHAR $6.65
- 52 Week High
- NBBK $21.05
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- NBBK 39.05
- PHAR 48.28
- Support Level
- NBBK $15.44
- PHAR $11.52
- Resistance Level
- NBBK $17.05
- PHAR $11.97
- Average True Range (ATR)
- NBBK 0.39
- PHAR 0.31
- MACD
- NBBK -0.03
- PHAR -0.08
- Stochastic Oscillator
- NBBK 45.09
- PHAR 15.06
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.